Wednesday, March 25, hear from Dr. Anthony M Magliocco, CEO and Founder of Protean BioDiagnostics, as he discusses the application of whole exome sequencing for guiding clinical trial enrollment for patients with cancer.
The remarkable advances in precision medicine are unfortunately not currently available to all patients, especially those being treated in community cancer settings. This growing “gap” is now challenging the health system to provide cost-effective, scalable, innovative solutions for underserved patients. Protean BioDiagnostics was founded to close this gap and accelerate access to precision oncology for all patients, regardless of where they live. To this end, Protean has created an adaptable and innovative framework for rapidly deploying the latest companion diagnostics. Protean’s simplification of universal access to complex diagnostics is poised to change the practice of precision oncology in the community and truly “close the gap.”
In this webinar, you will learn more about
Date: Wednesday, March 25, 2020
Time: 11 am EDT
The concept of precision medicine is beautifully simple: deliver the right treatment, every time, to the right patient. Making that concept a reality is more complex. Precision medicine is, after all, an entirely new approach to clinical medicine that leverages the power of big data and genomics to transform healthcare.
In a new on-demand webinar, Future of Genomics: The Precision Medicine Solution, our expert panel discusses how Aeon Global Health, the fastest growing clinical lab and healthcare services organization in the United States, partnered with QIAGEN to adopt an end-to-end automation solution that sped up their diagnostic output while lowering costs.
In 2013, when Aeon Global Health entered the hereditary cancer screening market, they knew that automation was critical to success. Together, QIAGEN Bioinformatics and Intel created a solution. By combining QIAGEN’s unparalleled expertise in genomics with Intel’s cutting-edge healthcare technology, the two companies enabled Aeon to provide faster, more comprehensive clinical insights than human cognition alone could permit. Today, one clinical geneticist at Aeon can process up to 50 tests per day.
Instead of taking weeks or months to make sense of a patient’s unique genetic profile, Aeon can now extract insights from colossal amounts of data in only a few minutes. And it’s not just the increase in efficiency that deserves attention. By partnering with Intel, QIAGEN has created an end-to-end solution that provides all workflow components, from analysis to interpretation to reporting, without having to hire hundreds of clinical geneticists and molecular pathologists, who would have to read reports and complete literature searches by hand. Clinical diagnostic test results are delivered quickly, accurately, and at a much lower cost.
As the amount of medical and biological data involved in medical diagnostics increases, so will the need for systems that help researchers, doctors and patients make sense of it. There are few medical advances as promising as precision medicine, and QIAGEN’s AI-based diagnostic tools—powered by Intel’s Scalable Solution Framework—are leading the way.
Join speakers Dr. Shawn Desai, Chief Technology Officer of Aeon Global Health, Dr. Ramon Felciano, Chief Technology Officer and Vice President of Strategy of QIAGEN Bioinformatics, and Kristina Kermanshahche, Global Director of Life Sciences at Intel Corporation, as they discuss how Aeon selected this powerful genomics solution and how you can build upon Aeon’s experience and accelerate your own path to success.
Watch Now — to learn how to put precision medicine on the fast track.
Josh Deignan, Associate Director at UCLA Molecular Diagnostics Laboratories, presents this webinar on clinical genomic sequencing. He discusses where we’ve been, where we are, and also have a few comments on where the field of molecular diagnostics and clinical genomic sequencing might be headed in the future.
Learn how he sees the challenges with clinical NGS - how to validate the accuracy of NGS tests and how results are actually being interpreted.
Clinical genomic sequencing: Where we’ve been, where we are, and where we’re going
Presenter: Josh Deignan, Ph.D., F.A.C.M.G, Associate Director, UCLA Molecular Diagnostics Laboratories
Each month we’re hosting a series of webinars introducing Ingenuity Pathway Analysis.
The first webinar each month is giving you an introduction to IPA while the following sessions are focusing on uploading you data or interpreting your results. Our experts Dr. Lynne Mullen and Dr. Jasmin Droege are hosting the webinars in U.S. and EU time zones, respectively.
You can find all our IPA support webinars here:
If you're interested in watching other webinars or videos, you can find our complete collection on tv.qiagenbioinformatics.com.
Webinar: Transcriptome analysis of pancreatic cancer exosomes involved in metastatic progression
Pancreatic cancer is one of the most lethal malignancies with a poor prognosis. Liquid biopsies are non-invasive methods for diagnostics to detect early stage cancer resulting in more successful treatment. One liquid biopsy technique is the detection of RNA from tumor-derived exosomes.
In this webinar you can learn how bioinformatics solutions can be used to analyze and interpret RNA-sequencing results from these exosome experiments, providing additional hypothesis on regulatory networks and potential isoforms of biological significance. We’ll examine the transcriptome of pancreatic tumor-derived exosomes that induce the formation of a liver metastatic niche, and demonstrate how our solutions can provide deep biological understanding in this process.
Find out how to:
https://clcbio.23video.com/v.ihtml/player.html?token=2d8ebf27b60d36957a4ba82940f712e0&source=embed&photo%5fid=13222910
Webinar
Studies of differential gene expression patterns using micro-array and RNA-seq technologies provide insight into the molecular mechanisms responsible for changes in gene expression. TRANSFAC, a unique knowledge-base containing published data on eukaryotic transcription factors and miRNAs, binding sites, and regulated genes can be leveraged to perform comparative promoter analyses of such high-throughput data, identifying the transcription factors most likely to have induced the experimentally observed pattern of gene expression.
In this webinar, we’ll discuss TRANSFAC’s method of virtual TSS calculation for defining promoter sequences and explore the impact that promoter assignments have on differential expression analysis results.
Role of microRNA-mRNA interactions in Endometrioid Endometrial Carcinoma, a Sample to Insight biological exploration
Endometrial adenoarcinoma is a common cause of gynecological cancer death in Europe and North America. The most dominant subtype, Endometrioid Endometrial Cancer (EEC) accounts for >80% of this cancer and is estrogen-dependent. At diagnosis, 75% of women have the disease confined to the uterus which is considered Stage One. Five-year survival for Stage One patients is 80%, however, about 15–20% develop metastasis. EEC is generally associated with good prognosis, however the clinical course may be unpredictable as four different EEC subtypes have been recently defined. One “transcriptome” subtype has been identified and presents a worse prognosis.
Jean-Noel Billaud, PhD, Principal Scientist, QIAGEN Bioinformatics, presents how our in silico solutions enabled us to analyze and identify the biological parameters involved in EEC tumor progression including signaling pathways, biological processes, and potential transcriptional drivers. Total RNA extracted from tissues obtained after surgical resection from three women at Stage One EEC was subjected to RNA-sequencing. The data was uploaded directly from the Sequence Read Archive and the FASTQ files were processed with Biomedical Genomics Workbench for secondary analysis including mapping, quantification and differential expression analysis. Through streamlined integration analyzed data was seamlessly uploaded to Ingenuity Pathway Analysis (IPA) and Ingenuity Variant Analysis (IVA) for biological interpretation, providing a sample to insight solution.
This webinar highlights our highly accurate and integrated end-to-end NGS analysis solution for the discovery of novel, and clinically relevant, rare and inherited disease causing variants, from various sample types in just one step.
Dr. Anika Joecker, Global Product Manager, presents the easy to use end-to-end hereditary disease workflows in Biomedical Genomics Workbench and Ingenuity Variant Analysis, as well as the Allele Frequency Community – an extensive, high-quality, ethnically diverse collection of human allele data for use as a reference set. The presentation will also touch upon the impact of accuracy and time-savings associated with reducing the number of false positives when searching for disease causing mutations in NGS data.
If you'd like to know more about how our hereditary disease solution addresses the NGS analysis bottleneck by delivering seamless and highly accurate end-to-end workflows for the identification and interpretation of causal variants you should read our recent press release. A laboratory using this new hereditary disease solution can achieve a case solve rate as high as 100%, while significantly reducing the rate of irrelevant variants for follow-up by 98% to 100%. These close to perfect solve rates are not possible using any other bioinformatics solution available in the market today, according to the latest benchmarking study that we presented at ASHG. The solution is cost-effective and can handle a high volume of samples (for example, 18,000 whole genomes per year).
Biomedical Genomics Workbench
Ingenuity Variant Analysis
Press release: QIAGEN launches new bioinformatics solution hereditary diseases
IPA Webinar: Part 1: Introduction to Ingenuity Pathway Analysis
Learn how to quickly and easily identify significant pathways, discover potential novel regulatory networks, and get the most out of your ‘omics data!
IPA has broadly been adopted by the life science research
community and is cited in thousands of articles for the analysis, integration,
and interpretation of data derived from ‘omics experiments, such as RNA-seq,
small RNA-seq, microarrays including miRNA and SNP, metabolomics, proteomics,
and small scale experiments. Hosted by two QIAGEN Senior Scientists, this
series will show you step-by-step how to implement and use IPA to get the most
out of your data.
Part 1: Introduction to the IPA Core Analysis
Learn how to view and interpret Core Analysis results in IPA,
which allows you to relate the molecules in your dataset to information in the
QIAGEN Knowledge Base. You will learn how to:
IPA Webinar: Part 2: Formatting and Uploading Your Dataset into IPA
IPA has broadly been adopted by the life science research community and is cited in thousands of articles for the analysis, integration, and interpretation of data derived from ‘omics experiments, such as RNA-seq, small RNA-seq, microarrays including miRNA and SNP, metabolomics, proteomics, and small scale experiments. Hosted by two QIAGEN Senior Scientists, this series will show you step-by-step how to implement and use IPA to get the most out of your data.
Part 2: Formatting and Uploading Your Dataset into IPA
Learn how to format your own data and upload it into IPA so that you can perform pathway visualization and various different types of analyses. Learn how to:
• Format and upload the data to be analyzed by IPA
• Explore your uploaded data and start an analysis
IPA Webinar: Part 3: Search and Explore in IPA
IPA has broadly been adopted by the life science research community and is cited in thousands of articles for the analysis, integration, and interpretation of data derived from ‘omics experiments, such as RNA-seq, small RNA-seq, microarrays including miRNA and SNP, metabolomics, proteomics, and small scale experiments. Hosted by two QIAGEN Senior Scientists, this series will show you step-by-step how to implement and use IPA to get the most out of your data.
Part 3: Search and Explore in IPA
Learn how IPA’s knowledge and discovery tools can accelerate your research with the use of recent literature findings and assistance in hypothesis generation. This webinar will describe how to explore inter-related information about genes, biological pathways and more using interactive and customized tools. Leverage this information instantly without needing to upload your data.
https://clcbio.23video.com/v.ihtml/player.html?token=bfd3de886d4ec51a9049b4450efcc553&source=embed&photo%5fid=57595637IPA Tips and Tricks
In this talk, Lynne Mullen, Ph.D. Senior Scientist, QIAGEN Digital Insights presents a series of helpful tips and tricks in QIAGEN IPA. Geared for all levels from beginning to advanced users, Dr. Mullen walk the audience through:
• Application Preferecnes
• Data Upload
• Creating Core Analyses
• My Pathway Tools
• Additional resources for IPA
Data Formatting in IPA
Learn how to format your dataset for upload and subsequent analysis in IPA. In this video tutorial, you will discover the best practices for structuring your dataset and the data measurement value types you can use for various IPA analyses.
Data Upload in IPA
Learn how to upload your dataset into IPA. In this video tutorial, you will discover the best practices for mapping the molecular identifiers and observation information that are present in your dataset. You will also learn how to annotate your dataset with metadata.
Take the first step in making the best out of your CLC Genomics Workbench workflow solution.
Our workbenches put practical bioinformatics in the hands of life scientists, and provide a smooth workflow solution from raw NGS data to interpretation, which you can use to generate biological insights.
Watch this webinar by Sr. Scientist Ajay Athavale to learn more about:
